Sali (HR)
{name}
{subtitle}
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)
city
~94 mi. (Split, Croatia, +144 more cities)
facility
Klinički Bolnički Centar Split ( Site 3202)
condition
Clear Cell Renal Cell Carcinoma
drug
belzutifan, +3 more drugs
drug type
immunotherapy, +1 more type
Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss
city
~94 mi. (Split, Croatia, +170 more cities)
facility
Novartis Investigative Site
biomarker
ER Negative, +4 more biomarkers
condition
Breast Carcinoma
drug
alpelisib, +1 more drug
drug type
chemotherapy, +1 more type
Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis
city
~94 mi. (Split, Croatia, +165 more cities)
facility
Klinicki bolnicki centar Split /ID# 230796
biomarker
del(11)(q10), +27 more biomarkers
condition
Myelofibrosis
drug
navitoclax, +1 more drug
drug type
targeted therapy